Osteologix Inc. (OLGX.OB) announced today that the company anticipates
that it will be prepared to file a marketing application in 2011 in the
European Union for its proprietary second-generation strontium therapy,
NB S101 (strontium malonate). If successful, this will be Osteologix'
first marketing approval of NB S101 for the treatment of postmenopausal
osteoporosis.
Following the successful completion of the company's initial Phase 2
study comparing NB S101 (strontium malonate) to Protelos® (strontium
ranelate), which is marketed by Les Laboratoires Servier (Servier),
Osteologix sought feedback on its development program from various
regulatory authorities. As a result of these discussions, Osteologix has
determined that the company will be positioned to pursue a European
Marketing Application for NB S101 as a treatment for post-menopausal
osteoporosis. The company expects that it can complete the additional
development work in 2010 and will be prepared to file a marketing
application during the first half of 2011. This pathway is in keeping
with the Company's overall strategy of developing its once-daily
strontium tablet for the osteoporosis market. Osteologix has initiated
discussion with potential regional and global partners and believes that
the selected partner(s) will be able to begin marketing the novel
product by 2012, providing them with at least 12 years of patent
protection in the European Union.